CALIXAR, develops new approaches to isolate in solution – with the highest purity levels – full-length membrane antigens and proteins, whilst keeping their structural and functional integrity. The company announced the completion of its second round of financing with its historical investors, Bpifrance (French public investment bank) and the Banque Populaire. The aim of this operation is to enable the licensing-out of its isolation technologies for complex therapeutic targets and viral antigens.

The company already holds 5 patents and has a unique approach which consists in preserving the native membrane proteins (70% therapeutic targets) involved in many diseases.

The new financing will enable Calixar to confirm its excellent results, especially on the development of new Influenza vaccines and high affinity antibodies to GPCRs; they will be available for partnership with the pharmaceutical industry by the second semester 2015.

We interviewed this promising company, you can see it at LaBiotechTour.com.

Concerning this second round of financing, Emmanuel Dejean, President & CEO of Calixar declared: “We are very proud of the continued confidence of our historical investors and financial partners. These funds will enable us to accelerate our internal research programs while continuing to offer our know-how and technologies to support our clients’ discovery programs in Europe, the United States and Japan”

Previous post

Flu Vaccine, from 18% to 23% Effective: Why?

Next post

ICON Completes the Acquisition of MediMedia Pharma Solutions

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.